Financial Performance - The company's operating revenue for the first half of 2024 was CNY 551,776,302.07, a decrease of 1.59% compared to CNY 560,696,060.91 in the same period last year[10]. - Net profit attributable to shareholders was CNY 9,262,843.84, a significant increase of 109.74% from a loss of CNY 95,107,757.01 in the previous year[10]. - The net profit after deducting non-recurring gains and losses reached CNY 9,489,955.97, up 111.59% from a loss of CNY 81,863,981.19 in the same period last year[10]. - The net cash flow from operating activities was CNY 13,195,640.30, a remarkable increase of 317.05% compared to a negative cash flow of CNY 6,079,577.63 in the previous year[10]. - Basic and diluted earnings per share were both CNY 0.0262, recovering from a loss of CNY 0.269 per share in the same period last year, marking a 109.74% improvement[10]. - The total assets at the end of the reporting period were CNY 2,902,617,652.42, reflecting a growth of 5.89% from CNY 2,741,165,147.34 at the end of the previous year[10]. - The net assets attributable to shareholders increased to CNY 1,873,871,204.61, a slight rise of 0.53% from CNY 1,864,035,046.79 at the end of the previous year[10]. - The company achieved total revenue of ¥551,776,302.07, a decrease of 1.59% compared to the same period last year[28]. - Revenue from medical testing services was ¥199,449,499.48, a decrease of 10.88% year-on-year[28]. - Revenue from reagent sales increased by 21.29% to ¥257,599,110.45[28]. - Revenue from equipment sales decreased by 29.39% to ¥17,045,915.08[28]. - The company achieved a significant reduction in operating costs, which fell by 16.88% to ¥263,774,077.25[31]. - The gross margin for the genetic testing industry improved by 8.80% to 52.20% despite a slight decline in revenue[33]. - The company reported a net profit contribution of -¥448.96 million from the sale of assets, which accounted for 35.60% of total net profit[42]. Business Operations - The main business focus is on high-throughput sequencing technology-based genetic testing services, including sales of related equipment and reagents[15]. - The company offers a comprehensive range of genetic testing services, including non-invasive prenatal testing (NIPT) for chromosomal abnormalities and single-gene disorders, covering 153 diseases[15]. - The "贝比安 Plus" NIPT service screens for 17 types of fetal chromosomal abnormalities and 76 types of microdeletion syndromes, enhancing prenatal diagnostic capabilities[16]. - The company utilizes third-generation sequencing technology for various genetic tests, including screening for thalassemia and spinal muscular atrophy, improving diagnostic accuracy[16]. - The "贝新安" newborn genetic screening covers 103 genetic diseases, identifying pathogenic or potentially pathogenic variants in 358 target genes[16]. - The company is committed to the clinical application of genetic sequencing technology, focusing on reproductive health, genetic disease testing, and tumor detection[15]. - The company aims to expand its market presence by providing integrated "product + service" solutions to hospitals and research institutions[15]. - The company is actively developing new products and technologies to enhance its service offerings in the genetic testing market[15]. - The company has launched the world's first clinical-level liver cancer early screening product "Lai Si Ning," validated by a prospective cohort study involving over 10,000 participants[17]. - The multi-cancer early screening product "Quan Si Ning" can screen for six major high-risk cancers in China, utilizing cfDNA multi-dimensional whole genome sequencing technology[17]. - The company has established a comprehensive range of sequencing analysis services, leveraging platforms like Illumina NovaSeq X Plus and PacBio Revio, covering various research fields including tumor and genetic disease studies[18]. - The company’s NIPT library preparation reagents utilize the proprietary EZ-PALO rapid library preparation method, enhancing efficiency and simplicity[19]. - The NextSeq CN500 platform has been adopted by over 200 qualified medical institutions and third-party testing organizations for large-scale clinical genetic testing[21]. - The Sequel® II CNDx platform is currently in the medical device registration phase, aimed at detecting complex single-gene diseases, particularly thalassemia[21]. - The NovaSeqTM 6000Dx-CN-BG platform is also in the medical device registration phase, designed for whole genome sequencing (WGS) and whole exome sequencing (WES) applications[21]. - The company offers a variety of reagents, including NIPT DNA extraction and purification reagents, which are characterized by their rapid and efficient performance[20]. - The company focuses on high-throughput second and third-generation sequencing hardware platforms to drive reagent sales in genetic and tumor fields[21]. - The company has developed a range of sequencing reagents in collaboration with Illumina, ensuring stable and accurate performance[20]. Market and Competitive Landscape - The company faces risks from intensified market competition and declining service prices, which could impact its market share and future performance[48]. - The company is at risk of technological and product innovation lag, which may lead to decreased market share and profit margins if it fails to keep pace with industry advancements[49]. - The company reported a potential risk of declining gross margins due to increased competition and regulatory uncertainties in the gene sequencing industry[50]. - Accounts receivable are increasing rapidly due to the company's business expansion, posing a risk of bad debts and potential liquidity issues[50]. - The company is focusing on new project development to address gaps in its testing product line, which may cause performance fluctuations[49]. - The company is actively managing risks associated with overseas operations, including compliance with international regulations and potential geopolitical impacts[50]. Governance and Compliance - The company received administrative regulatory measures from the China Securities Regulatory Commission due to internal control and accounting issues[61]. - The company has implemented a comprehensive internal control rectification plan, including enhancing procurement management and sales management processes[63]. - A third-party professional institution has been hired to comprehensively review and improve the company's internal control system[63]. - The company has established a special group for accounts receivable recovery, focusing on background checks and risk assessments for clients[62]. - The company has improved its internal reporting procedures to ensure timely feedback of significant information across departments[63]. - The company has completed initial rectification measures and will continue to enforce compliance with internal control standards[64]. - The company reported that the rectification activities have positively impacted its governance structure and operational transparency[64]. - The company has emphasized the importance of compliance training for its management and staff to enhance operational awareness and internal control supervision[65]. Shareholder and Equity Information - The company plans not to distribute cash dividends or issue bonus shares for the first half of 2024[54]. - A total of 85 employees participated in the employee stock ownership plan, holding a total of 2,823,000 shares, which represents 0.80% of the company's total equity[55]. - The first phase of the employee stock ownership plan has been extended for an additional 12 months, now set to expire on March 31, 2025[56]. - The total number of shares before the recent changes was 353,521,465, with a decrease of 18,233,989 shares due to the release of restricted shares, resulting in a new total of 318,258,593 shares[80]. - The proportion of restricted shares decreased from 15.13% to 9.97% after the changes, while the proportion of unrestricted shares increased from 84.87% to 90.03%[79]. - The company’s management has reduced their locked shares by 18,233,989, resulting in a new total of 35,262,872 restricted shares[80]. - The total amount of related party transactions for the reporting period was 30.88 million, with no significant impact on the company's financial status or independence[67]. Future Outlook and Strategy - The company plans to continue focusing on market expansion and new product development to drive future growth[100]. - The company is exploring potential mergers and acquisitions to strengthen its market position[116]. - The future outlook remains cautious due to market volatility and competitive pressures[116]. - The company has set performance guidance for the next quarter, anticipating a modest recovery in revenue growth[116]. Accounting and Financial Reporting - The financial statements are prepared based on the historical cost principle, ensuring reliable measurement of accounting elements[121]. - The company has not reported any significant events affecting its ability to continue operations[122]. - The company has undergone significant asset restructuring, acquiring 100% equity of Beijing Beirui and Kang Biotechnology Co., Ltd.[119]. - The stock name changed from "*ST Tianyi" to "Beirui Gene" following the completion of the asset restructuring[120]. - The company’s financial reporting is influenced by the judgments made regarding the timing and progress of performance obligations[199].

证券代码：000710 证券简称：贝瑞基因 公告编号：2024-048 成都市贝瑞和康基因技术股份有限公司 第十届监事会第六次会议决议公告 监事会审阅了《2024 年半年度报告全文及摘要》，认为其内容真实、准确、 完整，不存在任何的虚假记载、误导性陈述或者重大遗漏。 2、审议通过《关于向参股公司提供借款的议案》 表决结果：3 票同意，0 票反对，0 票弃权。 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、召开情况 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"）第十届监事会 第六次会议于 2024 年 8 月 22 日在北京市昌平区生命园路 4 号院 5 号楼 8 层 会议室以现场会议的方式召开，会议通知已于 2024 年 8 月 16 日以邮件形式发送 给各位监事，与会的各位监事均已知悉与所议事项相关的必要信息。本次监事会 会议应出席监事 3 名，实际出席会议监事 3 名，会议由监事会主席李翔东先生主 持，董事会秘书和证券事务代表列席了会议。会议的召开和表决程序符合有关法 律、行政法规、部门规章、规范性文件和公司章程的规定。 二、审议情况 1、审 ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2024-047 成都市贝瑞和康基因技术股份有限公司 关于向参股公司提供借款的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 一、借款事项概述 成都市贝瑞和康基因技术股份有限公司（以下简称"贝瑞基因""公司"或 "上市公司"）全资子公司福建贝瑞和康基因技术有限公司（以下简称"福建贝 瑞"）与福州滨海临空开发建设有限公司（以下简称"滨海开发"）合资设立的 福州新投生物科技产业园建设发展有限公司（以下简称"合资公司"）已于2024 年3月1日完成设立并投入运营，其中，滨海开发持有合资公司51%的股份，福建 贝瑞持有合资公司49%的股份，为满足合资公司开发建设运营资金需求，股东双 方拟对合资公司按持股比例提供借款。 合资公司股东双方拟于2024年10月31日前，按出资比例向其提供借款合计 3,000万元（其中滨海开发提供借款1,530万元，福建贝瑞提供借款1,470万元）， 借款期限为自实际提供借款之日起一年，借款利率按股东实际提供借款之日的一 年期LPR的140%计算。 本次借款不影响公司 ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2024-045 成都市贝瑞和康基因技术股份有限公司 第十届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、召开情况 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"）第十届董事会 第十次会议于 2024 年 8 月 22 日在北京市昌平区生命园路 4 号院 5 号楼 8 层 会议室以现场与通讯会议相结合的方式召开，会议通知已于 2024 年 8 月 16 日以 邮件形式发送给各位董事，与会的各位董事均已知悉与所议事项相关的必要信息。 本次董事会会议应出席董事 7 名，实际出席会议董事 7 名，会议由董事长高扬先 生主持，董事会秘书和证券事务代表列席了会议。会议的召开和表决程序符合有 关法律、行政法规、部门规章、规范性文件和公司章程的规定。 2、审议通过《关于向参股公司提供借款的议案》 表决结果：7 票同意，0 票反对，0 票弃权。 公司与福州滨海临空开发建设有限公司（以下简称"滨海开发"）合资设立 的福州新投生物科技产业园建设发展有限公司（以下简称"合资公司"）已于 20 ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2024-041 成都市贝瑞和康基因技术股份有限公司 第十届董事会第九次会议决议公告 1、审议通过《关于聘任公司董事会秘书的议案》 表决结果：7 票同意，0 票反对，0 票弃权。 艾雯露女士因工作调整申请辞去董事会秘书职务，辞职后将在公司担任其他 职务。 公司董事会同意聘任公司投资者关系总监许菲先生担任公司董事会秘书职 务，履行董事会秘书职责，任期自董事会审议通过之日起至第十届董事会届满之 日，提名委员会对任职资格进行了审查（简历见附件）。具体内容详见公司在巨 潮资讯网披露的《关于聘任公司董事会秘书的公告》（公告编号 2024-042）。 三、备查文件 1、第十届董事会第九次会议决议 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、召开情况 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"）第十届董事会 第九次会议于 2024 年 7 月 24 日在北京市昌平区生命园路 4 号院 5 号楼 8 层 会议室以现场与通讯会议相结合的方式召开，会议通知已于 2024 年 7 月 19 日以 邮件形式发送给 ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2024-043 成都市贝瑞和康基因技术股份有限公司 关于全资子公司出售资产进展暨完成产权过户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特此公告。 成都市贝瑞和康基因技术股份有限公司董事会 2024年7月24日 二、 交易进展 近日，福州产业园过户手续已全部办理完毕，福建产业园已变更登记到合资 公司福州新投生物科技产业园建设发展有限公司名下，并取得《不动产权证书》。 三、 备查文件 《不动产权证书》 一、 交易概述 成都市贝瑞和康基因技术股份有限公司（以下简称"贝瑞基因"或"公司"）分 别于2024年2月3日、2024年2月21日召开第十届董事会第六次会议、2024年第一 次临时股东大会，审议通过了《关于全资子公司对外投资成立合资公司的议案》、 《关于全资子公司出售资产的议案》等福州产业园交易相关议案。同意公司全资 子公司福建贝瑞和康基因技术有限公司（以下简称"福建贝瑞"）与福州滨海临 空开发建设有限公司共同成立合资公司福州新投生物科技产业园建设发展有限 公司（以下简称"福州新投"），由福州新 ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2024-042 成都市贝瑞和康基因技术股份有限公司 关于聘任公司董事会秘书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会秘书辞职情况 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"）董事会于近日 收到公司董事会秘书艾雯露女士的辞职报告，艾雯露女士因工作调整申请辞去 董事会秘书职务，辞职后将在公司担任其他职务。截至本公告日，艾雯露女士 未直接持有公司股份。根据《深圳证券交易所上市公司自律监管指引第1号—— 主板上市公司规范运作》等相关规定，艾雯露女士的辞职报告自送达公司董事 会时生效。艾雯露女士在担任公司董事会秘书期间恪尽职守、勤勉尽责，公司 和董事会对艾雯露女士在任职期间为公司发展所做的贡献表示衷心感谢！ 成都市贝瑞和康基因技术股份有限公司董事会 2024年7月24日 附件： 许菲先生简历 许菲先生，1986 年出生，中国国籍，本科学历，无境外永久居留权。许菲先 生 2012 年 5 月至 2024 年 6 月任职于北京数字政通科技股份有限公司，担任监 事、证券事务代表，现任公司 ...

暨股东持股比例变动超过1%的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 控股股东之一致行动人侯颖女士保证向本公司提供的信息内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 公司于近日通过中国证券登记结算有限责任公司深圳分公司（以下简称"中登结 算公司"）系统查询，获悉公司控股股东之一致行动人侯颖女士被司法拍卖的 5,284,925 股股票已完成过户登记手续，现将有关情况公告如下： 证券代码：000710 证券简称：贝瑞基因 公告编号：2024-040 成都市贝瑞和康基因技术股份有限公司 关于控股股东之一致行动人被司法拍卖的股份完成过户 1．基本情况 一、 本次司法拍卖的基本情况 成渝金融法院于 2024 年 7 月 15 日 10：00 时起至 2024 年 7 月 16 日 10：00 时 止在淘宝网司法拍卖网络平台公开拍卖公司控股股东之一致行动人侯颖女士持有的 公司 5,284,925 股股票，根据拍卖平台公示的《网络竞价成功确认书》，竞买人王 俊、王灯城竞拍成功，详 ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2024-039 成都市贝瑞和康基因技术股份有限公司 关于控股股东之一致行动人所持公司部分股份被司法拍卖的进展公告 | 序号 | 竞买人 | 竞买号 | 标的股数（股） | 成交价（元） | | --- | --- | --- | --- | --- | | 1 | 王俊 | W9786 | 500,000 | 3,295,000.00 | | 2 | 王俊 | O7258 | 500,000 | 3,315,000.00 | | 3 | 王俊 | H5117 | 500,000 | 3,335,000.00 | 1 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、本次拍卖标的物为公司控股股东之一致行动人侯颖女士持有的本公司 5,284,925 股股票，占其持有公司股份的比例为 26.16%，占公司总股本的比例为 1.49%。 上述将被司法拍卖的股份均为无限售流通股，均处于司法冻结状态。本次拍卖分 10 个标的进行，其中 9 标分别 500,000 股，1 标 784,925 股，均已竞拍成 ...

Financial Performance Forecast - The company forecasts a net profit attributable to shareholders of between 8 million and 12 million yuan for the first half of 2024, compared to a loss of 95.1078 million yuan in the same period last year[3]. - The net profit after deducting non-recurring gains and losses is expected to be between 7.5 million and 11.5 million yuan, compared to a loss of 81.8640 million yuan in the previous year[3]. - Basic earnings per share are projected to be between 0.0226 yuan and 0.0339 yuan, while the previous year recorded a loss of 0.2690 yuan per share[3]. Operational Improvements - The company has improved operational quality and effectively controlled costs, resulting in an increase in gross profit margin compared to the same period last year[5]. - The company has strengthened expense control, leading to a decrease in period expenses compared to the previous year[6]. - The loss from the fair value measurement of shares held in Prenetics has decreased compared to the same period last year[6]. Financial Reporting and Risks - The performance forecast is based on preliminary calculations by the company's finance department and has not yet been audited[4]. - The company emphasizes the importance of the upcoming 2024 semi-annual report for accurate financial data[8]. - Investors are advised to be aware of investment risks associated with the performance forecast[8]. Announcement Details - The announcement was made by the board of directors of Chengdu Berry Genomics Technology Co., Ltd. on July 12, 2024[9].